Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€176.05

€176.05

-3.730%
-6.85
-3.730%
€200.06
 
01.03.24 / Tradegate WKN: A1KBYX / Symbol: ZTS / Name: Zoetis / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Zoetis Inc. A Stock

Heavy losses for Zoetis Inc. A today as the stock fell by -€6.850 (-3.730%).
With 19 Buy predictions and not the single Sell prediction the community is currently very high on Zoetis Inc. A.
As a result the target price of 200 € shows a slightly positive potential of 13.6% compared to the current price of 176.05 € for Zoetis Inc. A.
Criterium "Business model" is seen as the biggest plus for Zoetis Inc. A stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Zoetis Inc. A in the next few years

Pros
?
M***** P*******
?
B****
?
S********** s********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Zoetis Inc. A vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Zoetis Inc. A -3.730% 0.991% 3.090% 16.286% 3.206% 42.535% 124.355%
Elanco Animal Health Inc. 0.410% -1.606% 5.000% 35.484% 8.728% -46.025% -
Pfizer Inc. -0.610% -3.340% -3.150% -35.871% -5.747% -11.367% -31.767%
Biogen Inc. 1.690% -2.335% -12.161% -21.286% -14.843% -11.131% -30.212%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-04

When examining the financials of Zoetis (NYSE: ZTS), a leading company in the pharmaceutical industry, a preliminary review reveals a robust picture with consistent growth in total assets over the last three years. This growth is coupled with a stable increase in shareholder equity, indicating prudent financial management and a strong balance sheet foundation. A deeper dive into the detailed numbers should provide further insights into the organization's financial health, as well as potential areas of caution.

Growing Top Line: Zoetis has demonstrated a steady increase in total revenues, with the trailing twelve-month (TTM) revenue at approximately $8.37 billion. The year-over-year quarterly revenue growth of 7.4% signals a solid capacity for expanding their market presence and sales effectiveness.

EBITDA and Operating Margins: The EBITDA and operating margins are notable strengths, with a TTM EBITDA of around $3.47 billion and an operating margin of 37.1%. These numbers suggest efficient operational management and profitability.

Comments

Prediction Buy
Perf. (%) 1.21%
Target price 203.214
Change
Ends at 20.02.25

Zoetis Inc. (NYSE: ZTS) had its price target raised by analysts at Piper Sandler from $215.00 to $220.00. They now have an "overweight" rating on the stock.
Ratings data for ZTS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 2.95%
Target price 242.424
Change
Ends at 14.02.25

Zoetis Inc. (NYSE: ZTS) had its price target raised by analysts at Barclays PLC from $255.00 to $260.00. They now have an "overweight" rating on the stock.
Ratings data for ZTS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 1.17%
Target price 208.236
Change
Ends at 17.01.25

Zoetis Inc. (NYSE: ZTS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $190.00 to $226.00. They now have a "buy" rating on the stock.
Ratings data for ZTS provided by MarketBeat
Show more

News

1 Magnificent S&P 500 Dividend Stock Down 23% to Buy Right Now: https://g.foolcdn.com/editorial/images/766397/gettyimages-1417884809.jpg
1 Magnificent S&P 500 Dividend Stock Down 23% to Buy Right Now

Particular financial metrics have been proven to indicate market-beating potential when analyzing stocks. Three examples are businesses with consistently growing dividend payments and a low payout

Zoetis (ZTS) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Zoetis (ZTS) Q4 2023 Earnings Call Transcript

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q4 2023 Earnings CallFeb 13, 2024, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Zoetis (ZTS) Q3 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Zoetis (ZTS) Q3 2023 Earnings Call Transcript

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q3 2023 Earnings CallNov 02, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com